SYNERGY BETWEEN PHORBOL ESTERS AND RETINOIC ACID IN INDUCING PROTEIN-KINASE-C ACTIVATION

被引:17
作者
BOUZINBASEGARD, H [1 ]
FAN, XT [1 ]
PERDERISET, M [1 ]
CASTAGNA, M [1 ]
机构
[1] HOP PAUL BROUSSE,INSERM,U268,F-94800 VILLEJUIF,FRANCE
关键词
D O I
10.1006/bbrc.1994.2433
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
All-trans retinoic acid (RA) activates brain protein kinase C (PKC) in a unique fashion. Co-factors such as Ca2+ or PtdSer are not required for histone phosphorylation. Binding experiments have provided evidence that RA does not act as a phorbol-ester-like activator. However, phorbol esters synergistically enhance this activation in a dose-dependent manner and increase the reaction rate up to five-fold when combined with 10 mu M RA. Phospholipid-interacting drugs such as phenothiazines and 1-N-(6 aminohexyl) 5-chloro-1-naphtalene-sulfonamide (W7), which compete with PtdSer and inhibit phorbol ester / PtdSer-mediated activation, have potentiating effects on the RA-mediated reaction. RA elicites Ca2+-dependent PKC autophosphorylation. The activation resulting from the combined treatment with PtdSer and RA is more than additive in the presence of Ca2+, indicating that PtdSer-and RA-binding sites are distinct. RA shares several characteristics of activation with sodium deoxycholate and arachidonic acid. These present results suggest that the direct activation of PKC may have physiological and/or pharmacological relevance in the signaling triggered by retinoids. (C) 1994 Academic Press, Inc.
引用
收藏
页码:112 / 119
页数:8
相关论文
共 26 条
[1]  
ASCHENDEL CL, 1983, BIOCHEM BIOPH RES CO, V111, P341
[2]   ROLE OF SUBSTRATE IN IMPARTING CALCIUM AND PHOSPHOLIPID REQUIREMENTS TO PROTEIN-KINASE-C ACTIVATION [J].
BAZZI, MD ;
NELSESTUEN, GL .
BIOCHEMISTRY, 1987, 26 (07) :1974-1982
[3]  
CASTAIGNE S, 1990, BLOOD, V76, P1704
[4]   FURTHER CHARACTERIZATION OF TUMOR-PROMOTER-MEDIATED ACTIVATION OF PROTEIN KINASE-C [J].
COUTURIER, A ;
BAZGAR, S ;
CASTAGNA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 121 (02) :448-455
[5]  
DASILVA C, 1990, CANCER RES, V50, P2081
[6]  
DE LUCA LM, 1991, FASEB J, V5, P2924
[7]  
FAN XT, 1991, CR ACAD SCI III-VIE, V313, P15
[8]  
FISHER SM, 1985, CARCINOGENESIS, V6, P575
[9]  
GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405
[10]   PHARMACOLOGY OF THE ISOQUINOLINE SULFONAMIDE PROTEIN-KINASE-C INHIBITORS [J].
HIDAKA, H ;
HAGIWARA, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (05) :162-164